Rimegepant

Rimegepant is a new prescription drug used to treat migraine headaches. It is a CGRP (calcitonin gene-related peptide) receptor antagonist, which works by blocking the activity of CGRP and its receptor, preventing the release of pain-causing inflammatory molecules. Rimegepant is taken as a pill once a day and works quickly to stop migraine headaches and reduce their frequency. It is an effective treatment for people with frequent migraine headaches.

Rimegepant is a medication used for both treating and preventing migraine headaches in adults [1]. Here's a breakdown of its key features:

Uses:

• Treats acute migraine attacks, with or without aura (warning symptoms before a migraine) [1].
• Prevents episodic migraine (occurs less than 15 days per month) by reducing the frequency of migraine attacks [1].

How it Works:

• Belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [1, 3].
• Migraines are thought to be caused by the release of CGRP, a substance that triggers inflammation and pain signals [2].
• Rimegepant blocks CGRP receptors, preventing them from receiving these pain signals and stopping a migraine attack or reducing its severity [2, 3].

Dosage and Administration:

• Comes as an orally disintegrating tablet (ODT) that dissolves quickly on or under the tongue [1, 3].
• For acute treatment: taken as a single dose at the first sign of a migraine [1].
• For prevention: typically taken every other day [1].
• Important to follow your doctor's instructions regarding dosage and frequency.

Safety and Side Effects:

• Generally well-tolerated [2].
• Potential side effects include nausea, dry mouth, and temporary liver enzyme elevations [1, 3].
• It's crucial to discuss any pre-existing health conditions or medications you are taking with your doctor before using rimegepant to avoid potential interactions [1].

Additional Points:

• Brand names for rimegepant include Nurtec ODT and Vydura [1].
• It is a relatively new medication, approved by the FDA in 2020 for acute treatment and by the European Commission in 2022 for both treatment and prevention [1].